Record Details

LONG-TERM ASSESSMENT OF EFFICACY AND SAFETY OF L1, AN ORAL IRON CHELATOR, IN TRANSFUSION DEPENDENT THALASSEMIA - INDIAN TRIAL

DSpace at IIT Bombay

View Archive Info
 
 
Field Value
 
Title LONG-TERM ASSESSMENT OF EFFICACY AND SAFETY OF L1, AN ORAL IRON CHELATOR, IN TRANSFUSION DEPENDENT THALASSEMIA - INDIAN TRIAL
 
Creator AGARWAL, MB
GUPTE, SS
VISWANATHAN, C
VASANDANI, D
RAMANATHAN, J
DESAI, N
PUNIYANI, RR
CHHABLANI, AT
 
Subject 1,2-dimethyl-3-hydroxypyrid-4-one l1
 
Description From August 1989 to May 1991, 52 patients with transfusion dependent thalassaemia major received L1 (1,2-dimethyl-3-hydroxypyrid-4-one), the oral iron chelator, for a period of 3-21 months (mean+/-SD: 14.2+/-6.8). Mean (+/-SD) urinary iron excretion varied from 6.2+/-4.6 mg/d on 25 mg/kg/d of L1 to 42.3+/-37.1 mg/d on 100 mg/kg/d of L1. Mean (+/-SD) drop in S ferritin was 1465+/-990 mug/l after 5.0+/-0.8 months to 3641.2+/-2299.3 mug/l after 20.1+/-0.9 months of therapy. There was no evidence of neutropenia, thrombocytopenia, ear or eye toxicity. L1-related arthralgia, which was reversible on dose reduction or stoppage, was seen in 20 patients (38.5%), while minor gastrointestinal (GI) tract symptoms occurred in seven (3.5%) cases. We conclude that although L1 is an effective iron chelator, further studies are required to understand the mechanism of L1 related arthralgia and also to find a safer but effective dose on which incidence of L1 related arthralgia is minimal.
 
Publisher BLACKWELL SCIENCE LTD
 
Date 2011-07-19T06:13:47Z
2011-12-26T12:51:02Z
2011-12-27T05:37:21Z
2011-07-19T06:13:47Z
2011-12-26T12:51:02Z
2011-12-27T05:37:21Z
1992
 
Type Article
 
Identifier BRITISH JOURNAL OF HAEMATOLOGY, 82(2), 460-466
0007-1048
http://dx.doi.org/10.1111/j.1365-2141.1992.tb06445.x
http://dspace.library.iitb.ac.in/xmlui/handle/10054/5194
http://hdl.handle.net/10054/5194
 
Language en